The story appears on

Page A12

August 25, 2016

GET this page in PDF

Free for subscribers

View shopping cart

Related News

HomeBusinessConsumer

Sale marks warming of relations

ASTRAZENECA plans to sell its molecule antibiotics business to Pfizer in a deal that will be valued over US$1.5 billion when rights, royalties and other payments are included.

The sale marks a thawing of relations between the UK company and New York-based Pfizer after an acrimonious battle to avoid a takeover just a few years ago.

Under the deal, AstraZeneca will sell the commercialization and development rights in most markets globally outside the United States. It includes an upfront payment of US$550 million.

Luke Miels, the head of the antibiotics business unit at AstraZeneca, says the company is “pleased that our strong science in antibiotics will continue to serve a critical public health need through Pfizer’s dedicated focus on infectious diseases.”


 

Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

娌叕缃戝畨澶 31010602000204鍙

Email this to your friend